PsyCap Recap: 3 Key Takeaways from the Albert Labs Psychedelic Capital Presentation

When it comes to radically transforming current healthcare paradigms, one company stands out with their novel strategies and dedicated mission to meet unmet medical needs: Albert Labs. The firm is poised to revolutionize modern medicine by providing accelerated access to safe and effective psychedelic assisted therapies in the UK and Europe. Here are three key takeaways from their January 2021 Psychedelic Capital presentation. 

Key Takeaway #1: Albert Labs is Pioneering Novel Mental Health Therapies Right Now

The current pandemic has undoubtedly exposed severe discrepancies in our collective approach to mental health treatment across the globe. Traditional therapies, such as SSRI’s, are effective for only part of the population and often come with unpleasant side effects for many. New treatments that are robust and efficacious for the population still suffering are urgently needed. This is where the team at Albert Labs truly shines, as they are well aware of the costly and time consuming process of clinical trials. They are the first psychedelics company pioneering faster pathways for such treatments in hospital settings across the UK and Europe. By utilizing the combined power of acclaimed academic institutions, existing hospital networks and established reimbursement mechanisms, the team at Albert Labs is fast-tracking radically effective new treatments, such as psilocybin therapy, to those who need it most. In doing so, they are also empowering clinicians and researchers to elevate their standard of care to the next level and bring their expertise to patients who desperately need it, starting in the UK and Europe and ultimately expanding across the globe.

Key Takeaway #2: Albert Labs is Ready to Enter a Massive Market with Real Solutions for Unmet Medical Needs

In the UK alone, there are 3 million people suffering from cancer, of which, 1.2 million suffer from cancer related anxiety and depression. Of these 1.2 million patients, half don’t have any means to deal with their anxiety and depression. When considering the world at large, it’s unsurprising that these numbers rise to staggering rates. Equally astonishing is the efficacy psilocybin, the active ingredient in magic mushrooms, has shown in radically treating this sort of anxiety and depression in terminally ill patients. In fact, a recent study out of Johns Hopkins showed psilocybin to be four times as efficacious as SSRI’s in the treatment of depression. Thus, by tackling this significant need for better treatment options for these end of life patients with psilocybin therapy, Albert Labs is poised to make a significant impact in the way we treat end of life care. In doing so, the team at Albert Labs is poised to enter a massive market with real solutions for unmet medical needs. 

Key Takeaway #3: Albert Labs’ Evidence Based Approach Positions them for Success

The modern psychedelic renaissance has brought with it a renewed interest and vigor in science and research. Major research institutions, such as Johns Hopkins University, NYU, and the Imperial College London have demonstrated the unparalleled efficacy of psychedelic medicine, such as psilocybin, in the treatment of various conditions that modern medicine is failing to effectively address. The team at Albert Labs is drawing upon this research and taking an evidence-based approach towards providing patients with accelerated access to safe and effective psychedelic assisted therapy. Additionally, they are basing intellectual property (IP) around novel formulations and working to scale their efforts by expanding into 10 centers with 1,000 patients by the end of the year. Given the incredible success psilocybin has garnered in the research arena, the team at Albert Labs is positioned for significant success by harnessing this evidence-based approach towards advancing patient care.  

Key Takeaway #3: Albert Labs’ Evidence Based Approach Positions them for Success

The modern psychedelic renaissance has brought with it a renewed interest and vigor in science and research. Major research institutions, such as Johns Hopkins University, NYU, and the Imperial College London have demonstrated the unparalleled efficacy of psychedelic medicine, such as psilocybin, in the treatment of various conditions that modern medicine is failing to effectively address. The team at Albert Labs is drawing upon this research and taking an evidence-based approach towards providing patients with accelerated access to safe and effective psychedelic assisted therapy. Additionally, they are basing intellectual property (IP) around novel formulations and working to scale their efforts by expanding into 10 centers with 1,000 patients by the end of the year. Given the incredible success psilocybin has garnered in the research arena, the team at Albert Labs is positioned for significant success by harnessing this evidence-based approach towards advancing patient care.